Quantcast
Home > Quotes > DRNA
DRNA

Dicerna Pharmaceuticals, Inc. Common Stock (DRNA) Quote & Summary Data

$12.23
*  
0.10
0.81%
Get DRNA Alerts
*Delayed - data as of Dec. 14, 2018 13:31 ET  -  Find a broker to begin trading DRNA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    DRNA Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 12.20 / $ 12.24
1 Year Target
22
Today's High / Low
$ 12.74 / $ 12.11
Share Volume
111,558
50 Day Avg. Daily Volume
563,605
Previous Close
$ 12.33
52 Week High / Low
$ 17.98 / $ 6.80
Market Cap
767,211,651
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.23
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.37

Intraday Chart

Shares Traded

Share Volume:
111,558
50 Day Avg. Daily Volume:
563,605

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.23

Trading Range

The current last sale of $12.23 is 79.85% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 12.74 $ 17.98
 Low: $ 12.11 $ 6.80

Company Description (as filed with the SEC)

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative subcutaneously delivered ribonucleic acid ("RNA") interference ("RNAi")-based pharmaceuticals using our GalXCTM RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Within these therapeutic areas, we believe our GalXC RNAi platform will allow us to build a broad pipeline of therapeutics with commercially attractive pharmaceutical properties, including a subcutaneous route of administration, infrequent dosing (e.g., dosing that is monthly or quarterly, and potentially even less frequent), high therapeutic index, and specificity to a single target gene.  ... More ...  


Risk Grade

Where does DRNA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 12.19
Open Date:
Dec. 14, 2018
Close Price:
$ 12.33
Close Date:
Dec. 13, 2018

Consensus Recommendation

Analyst Info